Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Alnylam Pharma (ALNY) yesterday and set a price target of $135. The company’s shares closed yesterday at $80.80.
Young wrote:
“: We reiterate our Overweight rating and 12-month price target of $135. Alnylam reported 4Q18 earnings that had few surprises, with Onpattro revenues of $12.1M coming in slightly above the $11-12M range pre- announced in early January. We remain bullish on the Onpattro launch, but think near-term focus in 2019 is on 1) late-stage pipeline readouts and 2) the next wave of programs entering the clinic. ALNY remains a top franchise pick in 2019. The company reiterated strong 4Q Onpattro launch metrics, but did not comment on how 1Q trends are tracking or provide 2019 sales guidance.”
According to TipRanks.com, Young is a 4-star analyst with an average return of 5.1% and a 47.6% success rate. Young covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Vertex Pharmaceuticals, and Sarepta Therapeutics.
Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $121.18, representing a 50.0% upside. In a report issued on January 28, Chardan Capital also maintained a Buy rating on the stock with a $150 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $153.99 and a one-year low of $60.27. Currently, Alnylam Pharma has an average volume of 930.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.
